Last reviewed · How we verify
NCT07066995: BAH2573-102
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
Phase 1, PHASE2 trial testing Mesothelin and Claudin 18.2 CAR-T cells in Pancreatic Cancer in 60 participants. Currently enrolling.
10 December 2027
Quick facts
| Lead sponsor | Essen Biotech |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 29 April 2025 |
| Primary completion | 10 December 2027 |
| Estimated completion | 28 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mesothelin and Claudin 18.2 CAR-T cells — full drug profile →
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Pancreatic Carcinoma — all drugs for Pancreatic Carcinoma →
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
- Pancreatic Cancer Stage IV — all drugs for Pancreatic Cancer Stage IV →
Sponsor
Essen Biotech — full company profile →
Who can join
Adults 21 to 90, any sex, with Pancreatic Cancer or Pancreatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.
Shen S, Ruan Z, Jiang B, Qiu W, et al · · 2026 · PMID 42039159 · DOI 10.3389/fimmu.2026.1764452 -
Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies.
Wang C, Zhang J, Chen ZK, Wang YG, et al · · 2026 · PMID 41810338 · DOI 10.5306/wjco.v17.i2.114107
Verify or expand the search:
- PubMed search for NCT07066995
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Essen Biotech trials
Trials by the same sponsor.
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07066982 — Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas · Phase 1, PHASE2 · recruiting
- NCT07067255 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer · Phase 1, PHASE2 · recruiting
- NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07066995 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Essen Biotech
- Last refreshed: 15 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07066995.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing